



**ONO PHARMACEUTICAL CO., LTD.**

8-2 Kyutaromachi 1-Chome, Chuo-ku, Osaka-shi, Osaka 541-8564

Phone +81 6 6263-5670

**Clinical Study Protocol**

**ONO-7579-01**

**EudraCT No 2016-004987-21**

**An open-label, multi-center, dose-escalation and expansion study to evaluate the safety and efficacy of ONO-7579 in patients with advanced solid tumors/ NTRK gene fusion positive advanced solid tumors**

This study was submitted to authorities, however the study was prematurely ended for business reasons. No patients were recruited in the UK. Only 1 patient was dosed in the United States (US). There were no safety concerns. Therefore no report was created.

Signature:

A handwritten signature in black ink, appearing to read "Mr. Kiyooki Idemitsu", written over a horizontal line.

Name: Mr Kiyooki Idemitsu

Title: Member of the Board of Directors, Executive Officer

Executive Officer/Executive Director

Clinical Development

Ono Pharmaceutical Co., Ltd.